Compare Piramal Healthcare with Panacea Biotech - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PIRAMAL ENTERPRISES vs PANACEA BIOTECH - Comparison Results

PIRAMAL ENTERPRISES     Change

Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More

PANACEA BIOTECH 
   Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PIRAMAL ENTERPRISES PANACEA BIOTECH PIRAMAL ENTERPRISES/
PANACEA BIOTECH
 
P/E (TTM) x 19.0 12.5 152.1% View Chart
P/BV x 1.2 3.0 40.2% View Chart
Dividend Yield % 1.5 0.0 -  

Financials

 PIRAMAL ENTERPRISES   PANACEA BIOTECH
EQUITY SHARE DATA
    PIRAMAL ENTERPRISES
Mar-19
PANACEA BIOTECH
Mar-18
PIRAMAL ENTERPRISES/
PANACEA BIOTECH
5-Yr Chart
Click to enlarge
High Rs3,303364 907.3%   
Low Rs1,797129 1,391.8%   
Sales per share (Unadj.) Rs716.596.8 740.3%  
Earnings per share (Unadj.) Rs79.7-12.4 -642.3%  
Cash flow per share (Unadj.) Rs107.9-2.9 -3,783.1%  
Dividends per share (Unadj.) Rs28.000-  
Dividend yield (eoy) %1.10-  
Book value per share (Unadj.) Rs1,477.550.4 2,931.7%  
Shares outstanding (eoy) m184.4561.25 301.1%   
Bonus/Rights/Conversions IS--  
Price / Sales ratio x3.62.5 139.7%   
Avg P/E ratio x32.0-19.9 -161.0%  
P/CF ratio (eoy) x23.6-86.4 -27.3%  
Price / Book Value ratio x1.74.9 35.3%  
Dividend payout %35.10-   
Avg Mkt Cap Rs m470,29215,101 3,114.3%   
No. of employees `0007.82.5 316.9%   
Total wages/salary Rs m22,5041,516 1,484.5%   
Avg. sales/employee Rs Th16,899.42,401.9 703.6%   
Avg. wages/employee Rs Th2,877.7614.2 468.5%   
Avg. net profit/employee Rs Th1,879.9-307.9 -610.5%   
INCOME DATA
Net Sales Rs m132,1535,928 2,229.3%  
Other income Rs m3,12882 3,800.7%   
Total revenues Rs m135,2816,010 2,250.9%   
Gross profit Rs m66,290845 7,842.1%  
Depreciation Rs m5,202585 888.7%   
Interest Rs m44,0971,006 4,384.3%   
Profit before tax Rs m20,119-664 -3,032.2%   
Minority Interest Rs m3,1940-   
Prior Period Items Rs m02 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m8,61199 8,733.6%   
Profit after tax Rs m14,701-760 -1,934.4%  
Gross profit margin %50.214.3 351.8%  
Effective tax rate %42.8-14.9 -288.0%   
Net profit margin %11.1-12.8 -86.8%  
BALANCE SHEET DATA
Current assets Rs m122,7425,603 2,190.5%   
Current liabilities Rs m310,8106,910 4,497.8%   
Net working cap to sales %-142.3-22.0 645.6%  
Current ratio x0.40.8 48.7%  
Inventory Days Days23206 11.2%  
Debtors Days Days3984 46.4%  
Net fixed assets Rs m116,9049,941 1,176.0%   
Share capital Rs m36961 601.8%   
"Free" reserves Rs m272,1613,026 8,995.3%   
Net worth Rs m272,5303,087 8,828.6%   
Long term debt Rs m270,1965,707 4,734.4%   
Total assets Rs m856,26116,076 5,326.5%  
Interest coverage x1.50.3 427.9%   
Debt to equity ratio x1.01.8 53.6%  
Sales to assets ratio x0.20.4 41.9%   
Return on assets %6.91.5 449.1%  
Return on equity %5.4-24.6 -21.9%  
Return on capital %12.43.9 317.2%  
Exports to sales %024.0 0.0%   
Imports to sales %017.5 0.0%   
Exports (fob) Rs mNA1,424 0.0%   
Imports (cif) Rs mNA1,040 0.0%   
Fx inflow Rs m15,2001,600 950.0%   
Fx outflow Rs m4,8891,131 432.1%   
Net fx Rs m10,312469 2,200.6%   
CASH FLOW
From Operations Rs m-115,9751,180 -9,826.7%  
From Investments Rs m-8,265553 -1,494.9%  
From Financial Activity Rs m107,525-1,644 -6,542.4%  
Net Cashflow Rs m-16,65090 -18,562.1%  

Share Holding

Indian Promoters % 52.9 74.5 71.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 4.0 0.6 666.7%  
FIIs % 26.6 1.3 2,046.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 16.5 23.6 69.9%  
Shareholders   93,274 10,259 909.2%  
Pledged promoter(s) holding % 0.0 35.1 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PIRAMAL ENTERPRISES With:   UNICHEM LAB  AUROBINDO PHARMA  IPCA LABS  GLENMARK PHARMA  SUN PHARMA  

Compare PIRAMAL ENTERPRISES With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 262 Points Lower; Oil & Gas and Banking Stocks Witness Selling(Closing)

Indian share markets witnessed negative trading activity throughout the day and ended lower. At the closing bell, the BSE Sensex stood lower by 262 points (down 0.7%).

Related Views on News

PIRAMAL ENTERPRISES Announces Quarterly Results (1QFY20); Net Profit Up 390.0% (Quarterly Result Update)

Aug 1, 2019 | Updated on Aug 1, 2019

For the quarter ended June 2019, PIRAMAL ENTERPRISES has posted a net profit of Rs 4 bn (up 390.0% YoY). Sales on the other hand came in at Rs 35 bn (up 20.8% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

PIRAMAL ENTERPRISES 2018-19 Annual Report Analysis (Annual Result Update)

Jul 9, 2019 | Updated on Jul 9, 2019

Here's an analysis of the annual report of PIRAMAL ENTERPRISES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of PIRAMAL ENTERPRISES. Also includes updates on the valuation of PIRAMAL ENTERPRISES.

PIRAMAL ENTERPRISES Announces Quarterly Results (4QFY19); Net Profit Down 91.4% (Quarterly Result Update)

Apr 30, 2019 | Updated on Apr 30, 2019

For the quarter ended March 2019, PIRAMAL ENTERPRISES has posted a net profit of Rs 3 bn (down 91.4% YoY). Sales on the other hand came in at Rs 37 bn (up 23.0% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

PANACEA BIOTECH 2017-18 Annual Report Analysis (Annual Result Update)

Mar 27, 2019 | Updated on Mar 27, 2019

Here's an analysis of the annual report of PANACEA BIOTECH for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of PANACEA BIOTECH. Also includes updates on the valuation of PANACEA BIOTECH.

PANACEA BIOTECH Announces Quarterly Results (3QFY19); Net Profit Down 137.1% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, PANACEA BIOTECH has posted a net profit of Rs 230 m (down 137.1% YoY). Sales on the other hand came in at Rs 1 bn (down 25.2% YoY). Read on for a complete analysis of PANACEA BIOTECH's quarterly results.

More Views on News

Most Popular

Buying these Eight Stocks is Like Owning Your Own Business(Profit Hunter)

Sep 5, 2019

Everyone dreams of owning a business. Here is your chance.

7 Stocks to Buy in the Market Today(The 5 Minute Wrapup)

Sep 5, 2019

The stock market had a four-year bull run starting September 2013. Are we seeing a similar pattern now?

Don't Buy Lakshmi Vilas Bank...Buy this Private Sector Bank with 74% Upside(The 5 Minute Wrapup)

Sep 4, 2019

Lakshmi Vilas Bank is in a vicious cycle. The stock is already down 57% in 2019. Despite this, the retail investors increased their holding.

Insider Buying Alert: Promoters Increase Stake in 8 High-Quality Smallcaps(Profit Hunter)

Sep 3, 2019

Insiders have increased their stakes in eight Hidden Treasure recommendations. Should you follow them?

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

PIRAMAL ENTERPRISES SHARE PRICE


Sep 16, 2019 03:35 PM

TRACK PIRAMAL ENTERPRISES

  • Track your investment in PIRAMAL ENTERPRISES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PIRAMAL ENTERPRISES

PIRAMAL ENTERPRISES - TTK HEALTHCARE COMPARISON

COMPARE PIRAMAL ENTERPRISES WITH

MARKET STATS